Literature DB >> 6272618

Cells originating from sarcoid granulomas in vitro.

T Okabe, A Suzuki, H Ishikawa, H Yotsumoto, N Ohsawa.   

Abstract

In an attempt to obtain in vitro experimental models for sarcoidosis, the primary cultures of granuloma cells were initiated with lymph nodes from 10 sarcoidosis patients. The cells migrating from tissue explants became confluent at 2 wk of culture. These cells exhibited overall morphologic features and enzymatic activities resembling those of in vivo granuloma epithelioid cells. By light and electron microscopy, the epithelioid cell in vitro contained a clear, large nucleus with 1 or 2 prominent nucleoli. The cytoplasm was characterized by the occurrence of lysosomal dense bodies and electron-lucent vacuoles, besides many mitochondria and well-developed Golgi complexes. The cell surface exhibited many processes, mainly lamellipodia. Large amounts of angiotensin converting enzyme activity (3.9 to 50.1 nmol/min/ml) lysozyme activity (3.9 to 23.0 micrograms/ml) were demonstrated in the medium used for culture. The results indicated that the major cell population grown in these cultures is derived from the epithelioid cells in sarcoid granulomas.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6272618     DOI: 10.1164/arrd.1981.124.5.608

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

1.  Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

Authors:  C Nataraj; M I Oliverio; R B Mannon; P J Mannon; L P Audoly; C S Amuchastegui; P Ruiz; O Smithies; T M Coffman
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Monocyte heterogeneity in angiotensin-converting enzyme induction mediated by autologous T lymphocytes.

Authors:  J H Ryu; Z Vuk-Pavlović; M S Rohrbach
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Levels of transferrin in bronchoalveolar lavage fluid in sarcoidosis.

Authors:  Masahiko Shigemura; Yasuyuki Nasuhara; Satoshi Konno; Takeshi Hattori; Chikara Shimizu; Kazuhiko Matsuno; Masaharu Nishimura
Journal:  Lung       Date:  2010-04       Impact factor: 2.584

4.  In vitro synthesis of angiotensin-converting enzyme by alveolar macrophages is increased in disseminated sarcoidosis.

Authors:  G Stanislas-Leguern; M Mordelet-Dambrine; D Dusser; M Huesca; J Chretien; G J Huchon
Journal:  Lung       Date:  1986       Impact factor: 2.584

5.  Increased angiotensin-converting enzyme in peripheral blood monocytes from patients with sarcoidosis.

Authors:  T Okabe; K Yamagata; M Fujisawa; J Watanabe; F Takaku; J J Lanzillo; B L Fanburg
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

6.  An in vitro model for the induction of angiotensin-converting enzyme in sarcoidosis: possible parallels to the immune response.

Authors:  Z Vuk-Pavlović; M S Rohrbach
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

7.  Comparison of the T lymphocyte-dependent induction of angiotensin-converting enzyme and leucine aminopeptidase in cultured human monocytes.

Authors:  M S Rohrbach; A K Conrad
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

8.  Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium.

Authors:  Mariko Negi; Tamiko Takemura; Josune Guzman; Keisuke Uchida; Asuka Furukawa; Yoshimi Suzuki; Tadatsune Iida; Ikuo Ishige; Junko Minami; Tetsuo Yamada; Hiroshi Kawachi; Ulrich Costabel; Yoshinobu Eishi
Journal:  Mod Pathol       Date:  2012-05-18       Impact factor: 7.842

9.  Propionibacterium acnes-derived insoluble immune complexes in sinus macrophages of lymph nodes affected by sarcoidosis.

Authors:  Yoshimi Suzuki; Keisuke Uchida; Tamiko Takemura; Masaki Sekine; Tomoki Tamura; Asuka Furukawa; Akira Hebisawa; Yumi Sakakibara; Nobuyasu Awano; Tomonari Amano; Daisuke Kobayashi; Mariko Negi; Tomoya Kakegawa; Yuriko Wada; Takashi Ito; Takashige Suzuki; Takumi Akashi; Yoshinobu Eishi
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.